Brief: Annexin Receives German Approval For ANXV Clinical Trial
May 11 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST: RECEIVES GERMAN APPROVAL FOR ANXV CLINICAL TRIAL NEXUS PHASE 2A STUDY TO EXPAND TO GERMANY FOR RVO AND DR Source text: ID:nMFNQw4Zn Further company coverage: ANNX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Resolves Rights Issue Of About SEK 20 Mln
Brief: Annexin Receives German Approval For ANXV Clinical Trial
Brief: Annexin Secures Financing Through Bridge Loan Facility, Plans Rights Issue
Brief: Annexin Pharmaceuticals Q4 Net Loss At SEK 10.5 Mln
Brief: Annexin Gets Approval For Phase 2A Study In Diabetic Retinopathy, RVO